Literature DB >> 8872954

Phosphorylation of cAMP responsive element binding protein after treatment of mesangial cells with high glucose plus TGF beta or PMA.

J I Kreisberg1, R A Radnik, S H Kreisberg.   

Abstract

We recently showed that mesangial cells treated with high glucose plus TGF beta or PMA demonstrated activation of a cAMP-response element (CRE) located in the 5' flanking region of the fibronectin gene. Gel shift mobility assays with a CRE oligonucleotide revealed multiple complexes that did not change in mobility or abundance under conditions of high glucose plus TGF beta or PMA. Here we show that treatment with cycloheximide to inhibit protein synthesis also did not change the DNA/protein complexes. These observations led us to conclude that post-translational modification of transcription factors may be responsible for the activation of the fibronectin gene observed under our experimental conditions. We identified the proteins complexed to CRE as CRE binding protein (CREB) and activating factor 1 (ATF1). This was accomplished by supershift assays and immunoblots. Two hours of high glucose plus TGF beta or 30 minutes of PMA caused a twofold elevation in phosphorylated CREB. Neither high glucose nor TGF beta alone caused phosphorylation of CREB. ATF-1 was not phosphorylated. We also show that high glucose plus TGF beta and PMA activated protein kinase C alpha; however, none of the agents tested stimulated intracellular cAMP levels, indicating that phosphorylation of CREB was independent of protein kinase A activation. These results demonstrate cross-talk between the protein kinase C and protein kinase A pathways in that agents which activate the protein kinase C pathway can stimulate phosphorylation of proteins that commonly serve as substrates for protein kinase A.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8872954     DOI: 10.1038/ki.1996.379

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  6 in total

1.  Role of connective tissue growth factor in the pathogenesis of diabetic nephropathy.

Authors:  N A Wahab; N Yevdokimova; B S Weston; T Roberts; X J Li; H Brinkman; R M Mason
Journal:  Biochem J       Date:  2001-10-01       Impact factor: 3.857

2.  Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db/db diabetic mice.

Authors:  F N Ziyadeh; B B Hoffman; D C Han; M C Iglesias-De La Cruz; S W Hong; M Isono; S Chen; T A McGowan; K Sharma
Journal:  Proc Natl Acad Sci U S A       Date:  2000-07-05       Impact factor: 11.205

3.  Transforming growth factor-beta signaling alters substrate permeability and tight junction protein expression at the blood-brain barrier during inflammatory pain.

Authors:  Patrick T Ronaldson; Kristin M Demarco; Lucy Sanchez-Covarrubias; Christine M Solinsky; Thomas P Davis
Journal:  J Cereb Blood Flow Metab       Date:  2009-03-25       Impact factor: 6.200

4.  Proteomic identification of 14-3-3zeta as an adapter for IGF-1 and Akt/GSK-3beta signaling and survival of renal mesangial cells.

Authors:  Lalit P Singh; Yan Jiang; Davis W Cheng
Journal:  Int J Biol Sci       Date:  2006-10-27       Impact factor: 6.580

5.  Effect of Sodium-Glucose Co-Transporter 2 Inhibitor, Dapagliflozin, on Renal Renin-Angiotensin System in an Animal Model of Type 2 Diabetes.

Authors:  Seok Joon Shin; Sungjin Chung; Soo Jung Kim; Eun-Mi Lee; Young-Hye Yoo; Ji-Won Kim; Yu-Bae Ahn; Eun-Sook Kim; Sung-Dae Moon; Myung-Jun Kim; Seung-Hyun Ko
Journal:  PLoS One       Date:  2016-11-01       Impact factor: 3.240

6.  Protein Kinase A Inhibitor H89 Attenuates Experimental Proliferative Vitreoretinopathy.

Authors:  Yali Lyu; Wei Xu; Jieping Zhang; Mengwen Li; Qingyi Xiang; Yao Li; Tianhao Tan; Qingjian Ou; Jingfa Zhang; Haibin Tian; Jing-Ying Xu; Caixia Jin; Furong Gao; Juan Wang; Weiye Li; Ao Rong; Lixia Lu; Guo-Tong Xu
Journal:  Invest Ophthalmol Vis Sci       Date:  2020-02-07       Impact factor: 4.799

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.